Orforglipron weight loss similar across menopausal stages, EASD analysis reports

The wire

1. 01Analyses presented at the European Association for the Study of Diabetes annual meeting in Milan, September 28 to October 2, found similar weight loss for women of different ages and life stages on orforglipron.
2. 02Clinicians have asked whether menopausal status blunts incretin response; the data suggest no age or life-stage signal in the trial populations analysed.
3. 03This is a conference presentation of subgroup analyses, not a prespecified primary endpoint; effect sizes and full peer-reviewed results are not yet published.

From the source

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.